Vaxart’s Oral COVID-19 Vaccine Chosen for Operation Warp Speed
The company’s oral COVID-19 vaccine has been chosen to participate in a non-human primate challenge study organized and funded by Operation Warp Speed.
Vaxart, a clinical-stage biotechnology company located in San Francisco, CA, announced on June 26, 2020 that its oral COVID-19 vaccine has been chosen to participate in a non-human primate challenge study organized and funded by Operation Warp Speed, a national program working to provide quantities of COVID-19 vaccines for the United States by January 2021.
“We are very pleased to be one of the few companies selected by Operation Warp Speed, and that ours is the only oral vaccine being evaluated. SARS-CoV-2, the coronavirus that causes COVID-19, is primarily transmitted by viral particles that enter through the mucosa-nose, mouth or eyes-strongly suggesting that mucosal immunity could serve as the first line of defense,” said Andrei Floroiu, CEO of Vaxart, in a company press release. “In addition, our vaccine is a room temperature-stable tablet, an enormous logistical advantage in large vaccination campaigns.”
Source: Vaxart
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
